Drug intelligence / Profile preview

citalopram + choline

Development stage
Preclinical
Lead developer
Lundbeck
Modality
Small Molecules
Administration
Oral
01

Overview

Citalopram + choline refers to the combination of two agents: **citalopram**, a selective serotonin reuptake inhibitor (SSRI) antidepressant, and **choline**, an essential nutrient (precursor to acetylcholine), or more specifically citicoline (CDP-choline), in published combination research. Citalopram functions as an SSRI, enhancing serotonergic neurotransmission by inhibiting the reuptake of serotonin in the central nervous system, thus alleviating depressive symptoms[2][4]. Choline (in the form of citicoline) acts as a neuroprotective agent and can elevate acetylcholine levels in the brain, which may support cognitive function and neural health. Studies have investigated this combination to address depression, showing that adjuvant administration of choline (citicoline) with citalopram improved antidepressant effects compared to citalopram alone, likely through synergistic impact on neurotransmitter systems[1][3].

Other names
choline + citalopram
02

Targets

α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)CHRNA7 (α7 nicotinic receptor)α9α10 nAChR (α9α10 nicotinic receptor)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on citalopram + choline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on citalopram + choline.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call